Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Finlabo SIM Spa
$10.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG’s Bayer HealthCare Pharmaceuticals And Onyx Pharmaceuticals, Inc. Present Positive Phase III Data On Sorafenib


Monday, 3 Jun 2013 01:08am EDT 

Bayer AG announced that its unit, Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced positive data from the Phase III DECISION trial investigating the use of sorafenib (Nexavar) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer. Sorafenib extended progression-free survival (PFS) compared to placebo, which represents a 41% reduction in the risk of progression or death for patients who received sorafenib compared to placebo treated patients. Bayer AG plans to submit the Phase III DECISION data as the basis to apply for marketing authorization of sorafenib in the treatment of RAI-refractory differentiated thyroid cancer. 

Company Quote

114.0
-1.0 -0.87%
19 Dec 2014